B
B. Corkery
Researcher at Dublin City University
Publications - 9
Citations - 500
B. Corkery is an academic researcher from Dublin City University. The author has contributed to research in topics: Dasatinib & Triple-negative breast cancer. The author has an hindex of 5, co-authored 9 publications receiving 449 citations.
Papers
More filters
Journal ArticleDOI
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
TL;DR: Although the TNBC cells are less sensitive to EGFR inhibition than the HER-2-positive cell lines, gefitinib enhanced response to chemotherapy and combined with carboplatin and docetaxel warrants further investigation in TNBC.
Journal ArticleDOI
Src: a potential target for the treatment of triple-negative breast cancer
D. Tryfonopoulos,Siun Walsh,Denis M. Collins,Louise Flanagan,Cecily Quinn,B. Corkery,Enda W. McDermott,Denis Evoy,Aisling Pierce,Norma O'Donovan,John Crown,Michael J. Duffy +11 more
TL;DR: It is concluded that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.
Journal ArticleDOI
EGFR and HER2 inhibition in pancreatic cancer
Naomi Walsh,Susan Kennedy,Annemarie Larkin,B. Corkery,Lorraine O'Driscoll,Martin Clynes,John Crown,Norma O'Donovan +7 more
TL;DR: Based on in vitro results, lapatinib may provide clinical benefit in EGFR positive pancreatic ductal adenocarcinoma, and is likely to identify a subset of patient most likely to benefit from lapatinIB.
Journal ArticleDOI
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
Patricia Gaule,Nupur Mukherjee,B. Corkery,Alex J Eustace,Kathy Gately,Sandra Roche,Robert O'Connor,Kenneth J. O'Byrne,Naomi Walsh,Michael J. Duffy,John Crown,Norma O'Donovan +11 more
TL;DR: If these in vitro findings can be extrapolated to human cancer treatment, combined treatment with dasatinib and a c-Met inhibitor may block the development of acquired resistance and improve response rates to dAsatinib treatment in TNBC.
Journal ArticleDOI
Activity of dasatinib with chemotherapy in triple-negative breast cancer cells
TL;DR: The findings show that the combination of dasatinib with either 5'-5'-DFUR or cisplatin is synergistic in TNBC cell lines, and suggest that combinations of d asatinIB with chemotherapy may improve response in triple negative breast cancer patients.